Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Evolution of appetite sensation |
Satiety assessment, measured in eva scale (%) |
It is measured twice, both at the end of taking the product after 60 days (placebo and experimental product) |
|
Primary |
Sensation of appetite before intaking the product under investigation |
Satiety assessment, measured in eva scale (%) |
It is measured twice, both at the end of taking the product after 60 days (placebo and experimental product) |
|
Primary |
Area under the curve of the evolution of the appetite sensation from instant zero ingestion to instant ingestion of 60 minutes |
Satiety assessment, measured in eva scale (%) |
It is measured twice, both at the end of taking the product after 60 days (placebo and experimental product) |
|
Primary |
Average of the appetite sensation during the 60 minutes after intake of the experimented product |
Satiety assessment, measured in eva scale (%) |
It is measured twice, both at the end of taking the product after 60 days (placebo and experimental product) |
|
Primary |
Decrease in the sensation of appetite suffering from subjects when consuming the product in experimentation |
Satiety assessment, measured in eva scale (%) |
It is measured twice, both at the end of taking the product after 60 days (placebo and experimental product) |
|
Primary |
Area under the curve of the evolution of the appetite feeling from the 60 minutes post-intake instantly 240 minutes post-intake. |
Satiety assessment, measured in eva scale (%) |
It is measured twice, both at the end of taking the product after 60 days (placebo and experimental product) |
|
Primary |
Appetite sensation at 240 minutes post-ingestion and area under the curve of the evolution of appetite feeling from instant zero post-intake to instant 240 minutes post-intake |
Satiety assessment, measured in eva scale (%) |
It is measured twice, both at the end of taking the product after 60 days (placebo and experimental product) |
|
Primary |
Appetite feeling immediately after ad-libitum food |
Satiety assessment, measured in eva scale (%) |
It is measured twice, both at the end of taking the product after 60 days (placebo and experimental product) |
|
Primary |
Amount of energy consumed during the ad-libitum meal |
Satiety assessment, measured in kcal with the weighing of the food consumed in the ad libitum test |
It is measured twice, both at the end of taking the product after 60 days (placebo and experimental product) |
|
Primary |
Satiety quotient (SQ) |
Satiety assessment, measured in kcal with the weighing of the food consumed in the ad libitum test |
It is measured twice, both at the end of taking the product after 60 days (placebo and experimental product) |
|
Secondary |
Insulinemia |
Hormonal analysis, measured in mU/L |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. And in the ad libitum test. |
|
Secondary |
Leptin |
Hormonal analysis, measured in ng/dL |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. And in the ad libitum test. |
|
Secondary |
Adiponectin |
Hormonal analysis, measured in µg/mL |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. And in the ad libitum test. |
|
Secondary |
Ghrelin (GHRL) |
Hormonal analysis, measured in ng/ml |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. And in the ad libitum test. |
|
Secondary |
Tyrosine Peptide Tyrosine (PYY) |
Hormonal analysis, measured in pg/mL |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. And in the ad libitum test. |
|
Secondary |
Glucagon Like Peptide - 1 (GLP-1) |
Hormonal analysis, measured in ng/mL |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. And in the ad libitum test. |
|
Secondary |
Blood glucose |
Glycidic analysis, measured in mg/dL |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. And in the ad libitum test. |
|
Secondary |
Glycosylated hemoglobin (HBA1c) |
Glycidic analysis, measured in % |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. |
|
Secondary |
Peripheral insulin resistance (HOMA-IR) |
Glycidic analysis |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. |
|
Secondary |
Total Cholesterol |
Lipidic profile, measured in mg/dl |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. |
|
Secondary |
LDL - Cholesterol |
Lipidic profile, measured in mg/dl |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. |
|
Secondary |
HDL - Cholesterol |
Lipidic profile, measured in mg/dl |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. |
|
Secondary |
Triglycerides |
Lipidic profile, measured in mg/dl |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. |
|
Secondary |
Fat mass |
Bioimpedance, in Kg. For this we will use a TANITA |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. |
|
Secondary |
Muscle mass |
Bioimpedance, in Kg. For this we will use a TANITA |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. |
|
Secondary |
Body mass index |
Bioimpedance, in Kg/m2. For this we will use a TANITA |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. |
|
Secondary |
Physical activity |
Measured in MET, with Actigraph wGT3X-BT |
It will be measured for 3 days before and after the consumption time (60 days) with the experimental product and the placebo product. |
|
Secondary |
Gastrointestinal Quality of Life Test |
GIQLI |
It is measured before and after the consumption time (60 days) with the experimental product and the placebo product. |
|
Secondary |
Quality of Life Test |
WHOQOL BREF |
It is measured before and after the consumption time (60 days) with the experimental product and the placebo product. |
|
Secondary |
Liver safety variables |
It is a blood test that measures the presence of some enzymes, proteins and bilirubin in the blood, with the aim of determining if there is any alteration in the liver. Enzyme GPT, GOT, Gamma GT, LDH, alkaline phosphatase and bilirubin (UI/L) |
It is measured on an empty stomach, before and after the consumption time (60 days) with the experimental product and the placebo product. |
|